OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shah Discusses the BRIGHTER Study in Gastric Cancer

August 9th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Eyre on Results of Venetoclax in Relapsed/Refractory MCL

August 9th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the results of single-agent venetoclax (Venclexta) in patients with relapsed/refractory mantle cell lymphoma.

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

August 9th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Dr. Bosse on Challenges With Immunotherapy in Pediatric Cancers

August 9th 2018

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Dr. Bota on Marizomib in Patients with Glioma

August 8th 2018

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Dr. Barrientos on Advances in the Treatment Landscape for Patients With CLL

August 8th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in Myeloma

August 8th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHL

August 8th 2018

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

Dr. Wistuba on Biomarkers for Immunotherapy in Lung Cancer

August 8th 2018

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Medicine, The University of Texas MD Anderson Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

August 8th 2018

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer

August 8th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.

Dr. Flinn on the iNNOVATE Trial in Waldenstrom Macroglobulinemia

August 8th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.

Dr. Samuelson on the Comorbidities that Affect Treatment Decisions in Prostate Cancer

August 8th 2018

Scott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.

Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma

August 8th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.

Dr. Borgen Discusses Axillary Node Dissection in Early-Stage Breast Cancer

August 7th 2018

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, discusses axillary node dissection in patients with early-stage breast cancer.

Dr. Finn Discusses Sequencing Therapy for HCC

August 7th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

Dr. Drake on the Role of Cytoreductive Nephrectomy in RCC

August 7th 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.

Dr. Hurvitz on the Impact of Biosimilars

August 7th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the impact of biosimilars in the treatment of patients with breast cancer.

Dr. Bailey Discusses the Treatment of Pediatric Patients With Sarcoma

August 7th 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Dr. Bekaii-Saab Reflects on the Findings of the ReDOS Trial in mCRC

August 7th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.